245 results on '"Lorent, Natalie"'
Search Results
2. Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC)
3. Individual level analysis of digital proximity tracing for COVID-19 in Belgium highlights major bottlenecks
4. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection
5. Sputum from patients with primary ciliary dyskinesia contains high numbers of dysfunctional neutrophils and inhibits efferocytosis
6. Thromboprophylaxis in COVID‐19: Weight and severity adjusted intensified dosing
7. Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
8. Does pre-existing respiratory disease affect 3-month outcome following COVID hospitalisation across 4 waves: a prospective cohort analysis.
9. Visualizing in deceased COVID-19 patients how SARS-CoV-2 attacks the respiratory and olfactory mucosae but spares the olfactory bulb
10. Association between upper and lower respiratory disease among patients with primary ciliary dyskinesia: an international study
11. Impact of COVID-19: urging a need for multi-domain assessment of COVID-19 inpatients
12. Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)
13. COVID-19 in lung transplant patients: A case series
14. The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients
15. The Association between Bronchiectasis and Chronic Obstructive Pulmonary Disease: Data from the European Bronchiectasis Registry (EMBARC).
16. COVID-19 Outcomes in Lung Transplant Recipients Following Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab During the Omicron BA.5 Surge: A Single Center Analysis
17. Challenges and knowledge gaps in the management of non-tuberculous mycobacterial pulmonary disease in sub-Saharan African countries with a high tuberculosis burden: a scoping review
18. Hypoglycaemia after Initiation of CFTR Modulator Therapy in a Cystic Fibrosis Patient without Diabetes
19. Systemic Inflammation and Myelofibrosis in a Patient with Takenouchi-Kosaki Syndrome due to CDC42 Tyr64Cys Mutation
20. Defining Polysaccharide Antibody Deficiency: Measurement of Anti-Pneumococcal Antibodies and Anti-Salmonella typhi Antibodies in a Cohort of Patients with Recurrent Infections
21. A BEAT-PCD consensus statement: a core outcome set for pulmonary disease interventions in primary ciliary dyskinesia
22. Association between upper and lower respiratory disease among patients with primary ciliary dyskinesia: an international study
23. The bronchiectasis exacerbation definition in a real-world setting: data from the EMBARC registry
24. Preliminary results from the “Genes encoding complex ciliopathies of bronchiectasis” GECCO study: An EMBARC project
25. Variability of lung function in patients with primary ciliary dyskinesia (PCD): longitudinal analysis from the PROVALF-PCD cohort, a BEAT-PCD Collaboration
26. Proteinase 3 as a marker of clinical severity in bronchiectasis: Data from the EMBARC-BRIDGE study
27. Addressing an unmet need in the management of nontuberculous mycobacterial infections in Belgium: 1 year experience of the NTM consilium
28. Understanding patients at risk of NTM-PD using a modified Delphi process
29. Alpha-1 antitrypsin deficiency genotypes in a large international cohort study of bronchiectasis (EMBARC BRIDGE)
30. NTM pulmonary disease in a referral center: treatment adherence and outcomes in a retrospective cohort.
31. Convergent validity of the Bronchiectasis Impact Measure: data from the EMBARC-BRIDGE study
32. Individual level analysis of digital proximity tracing for COVID-19 in Belgium highlights major bottlenecks
33. Aspiration Pneumonia After External Dacryocystorhinostomy Under Local Anesthesia Without Sedation: A Case Report
34. Characteristics of Otologic Disease Among Patients With Primary Ciliary Dyskinesia
35. Clinical relevance of pulmonary non-tuberculous mycobacterial isolates in three reference centres in Belgium: a multicentre retrospective analysis
36. A BEAT-PCD consensus statement: a core outcome set for pulmonary disease interventions in primary ciliary dyskinesia.
37. Centralised Air Sampling from a Ventilation System for the Surveillance of Respiratory Pathogens
38. Sinonasal disease among patients with primary ciliary dyskinesia – an international study
39. Otologic disease among patients with primary ciliary dyskinesia - an international observational study
40. Additional file 1 of Sputum from patients with primary ciliary dyskinesia contains high numbers of dysfunctional neutrophils and inhibits efferocytosis
41. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease:A NTM-NET study
42. The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN
43. Lung Aeration in COVID-19 Pneumonia by Ultrasonography and Computed Tomography
44. Safety and Outcomes of Amikacin Liposome Inhalation Suspension for Mycobacterium abscessus Pulmonary Disease: A NTM-NET study
45. Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: a NTM-NET study.
46. Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: a NTM-NET study
47. The disease-specific clinical trial network for primary ciliary dyskinesia:PCD-CTN
48. Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge
49. Hypoglycemia after initiation of CFTR modulator therapy in a cystic fibrosis patient without diabetes
50. Repolarization abnormalities on admission predict 1-year outcome in COVID-19 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.